Provide lobbying support on key issues and track relevant federal policy developments that could impact the pharmaceutical, healthcare industries generally and Bayer specifically.
2025 · 4th Quarter (Oct 1 - Dec 31)
BAYER U.S. LLC
Filed by HB STRATEGIES (FKA HUSCH BLACKWELL STRATEGIES).
Open official filingSource-reported fields
Filing overview
- Type
- 4th Quarter - Report
- Posted
- Jan 19, 2026
- Income
- $120,000.00
- Expenses
- Not reported
- Client
- BAYER U.S. LLC
- Filing UUID
- caaa0903-efa8-4ffc-b4de-08f78ed30608
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Provide lobbying support on key issues and track relevant federal policy developments that could impact the pharmaceutical, healthcare industries generally and Bayer specifically.
Provide lobbying support on key issues and track relevant federal policy developments that could impact the pharmaceutical, healthcare industries generally and Bayer specifically.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.